Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Safusidenib in Participants With Grade 2 Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma

NCT07712757 is registered in ClinicalTrials.gov with Nuvation Bio Inc. as lead sponsor.

NCT NCT07712757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07712757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Safusidenib in Participants With Grade 2 Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma
Lead sponsor
Nuvation Bio Inc.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
March 31, 2027
Completion date
March 31, 2032
Enrollment
140 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma idh mutant grade 2, grade 2 glioma (astrocytoma or oligodendroglioma) with an idh1 mutation, idh-mutant gliomas, oligodendroglioma, oligodendroglioma idh-mutant and 1p/19q-codeleted